Weight Related Comorbidity / With/without Diabetes Mellitus, Type 2 / Obesity Or Overweight · Phase 3 Trial

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

ClinicalTrials.gov · August 20, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a planned Phase 3 randomized trial of AZD6234 versus placebo in adults with obesity or overweight and weight-related comorbidity, with or without type 2 diabetes. The trial is registered but has not yet begun recruitment and no efficacy or safety data are available.

What was studied

Phase 3, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2; age from 18 Years. Intervention: AZD6234. Compared with: Placebo — Placebo Comparator. n = 500. 88 sites across 11 countries.

Key findings

Safety

No efficacy, safety, or any outcome data are reported in this registry record.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a registered Phase 3 trial not yet recruiting with no results posted; it describes a planned study design and primary endpoint only.

Study design

As stated by the source record.

MethodsPrimary outcome measure: Percent change in body weight from baseline at 68 weeks of treatment (assessed at 68 weeks)

DesignPhase 3, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose

PopulationObesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2; age from 18 Years

Sample size500

InterventionAZD6234

ComparatorPlacebo — Placebo Comparator

Setting88 sites across 11 countries

Reported figures

Quoted from the source exactly as published.

Planned sample size500

PhasePhase 3

Primary outcome measurePercent change in body weight from baseline at 68 weeks of treatment

Treatment duration68 weeks

Caveats

Recruitment has not yet started; no participant enrollment data available.
No efficacy, safety, or any outcome data are reported in this registry record.
Randomization method, blinding, and comparator details not specified.
Study registration only; results will be available only after trial completion and publication.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

strong

Phase 3 randomized controlled trial with placebo comparator planned.

Directness

strong

Primary outcome is percent change in body weight, a clinically relevant measure.

Consistency

insufficient

No results reported; consistency cannot be assessed.

Risk of bias

insufficient

Study design elements (blinding, randomization method) not detailed in registry record.

Sample adequacy

moderate

Estimated 500 participants; adequate for Phase 3 but enrollment not yet started.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07776509). This is a study registration, not published results. Lead sponsor: AstraZeneca. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 500 participants (ESTIMATED). Conditions: Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2. Interventions: DRUG: AZD6234; DRUG: Placebo. Primary outcome measures: Percent change in body weight from baseline at 68 weeks of treatment , 68 weeks. Brief summary: The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

NCT07776509Weight Related ComorbidityWith/without Diabetes Mellitus, Type 2Obesity Or OverweightAstraZenecaAZD6234